Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE Trial,European Urology

当前位置： X-MOL 学术 › Eur. Urol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Risk-adjusted Screening for Prostate Cancer—Defining the Low-risk Group by Data from the PROBASE Trial
European Urology ( IF 25.3 ) Pub Date : 2024-05-15 , DOI: 10.1016/j.eururo.2024.04.030
Agne Krilaviciute ₁ , Rudolf Kaaks ₂ , Petra Seibold ₁ , Maxime de Vrieze ₁ , Jale Lakes ₃ , Jan Philipp Radtke ₃ , Markus Kuczyk ₄ , Nina N Harke ₄ , Jürgen Debus ₅ , Christoph A Fink ₅ , Kathleen Herkommer ₆ , Jürgen E Gschwend ₆ , Valentin H Meissner ₆ , Axel Benner ₇ , Glen Kristiansen ₈ , Boris Hadaschik ₉ , Christian Arsov ₃ , Lars Schimmöller ₁₀ , Gerald Antoch ₁₁ , Frederik L Giesel ₁₂ , Marcus Makowski ₁₂ , Frank Wacker ₁₃ , Heinz-Peter Schlemmer ₁₄ , Nikolaus Becker ₁ , Peter Albers ₁₅

Affiliation

Division of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
Department of Urology, Hannover Medical School, Hannover, Germany.
Department of Radiation Oncology, Heidelberg University Hospital, Ruprecht Karls University Heidelberg, Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Urology, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany.
Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Institute of Pathology, University Hospital Bonn, Bonn, Germany.
Department of Urology, University of Duisburg-Essen and German Cancer Consortium (dktk), University Hospital Essen, Essen, Germany.
Department of Diagnostic and Interventional Radiology, Medical Faculty, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany; Department of Diagnostic, Interventional Radiology and Nuclear Medicine, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.
Department of Nuclear Medicine, Medical Faculty, Duesseldorf, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.
Institute of Diagnostic and Interventional Radiology, Technical University Munich, Munich, Germany.
Institute of Diagnostic and Interventional Radiology, Medical University Hannover, Hannover, Germany.
Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Division of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Urology, University Hospital, Medical Faculty, Heinrich-Heine University Duesseldorf, Duesseldorf, Germany.

Risk-adjusted screening for prostate cancer (PCa) aims to reduce harms by less frequent retesting, especially in men at a low risk of PCa. Definitions of low risk are based mainly on studies in men starting screening at age 55–60 yr.

中文翻译：